Cargando…

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections

INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stewart, Cassie L., Turner, Michelle S., Frens, Jeremy J., Snider, Cynthia B., Smith, Jordan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446369/ https://www.ncbi.nlm.nih.gov/pubmed/28386776 http://dx.doi.org/10.1007/s40121-017-0156-z

Ejemplares similares

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes
por: Redell, Mark
Publicado: (2020)

Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs
por: Ahiskali, Aileen, et al.
Publicado: (2020)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

1845. Oritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections
por: Moenster, Ryan P, et al.
Publicado: (2022)

Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience
por: Brownell, Lauren E., et al.
Publicado: (2020)

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program
por: Redell, Mark, et al.
Publicado: (2018)

1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation
por: Morrisette, Taylor, et al.
Publicado: (2020)

1015. Real World Use of Dalbavancin and Oritavancin for Optimized Outpatient Antimicrobial Therapy in Patients Inappropriate for Standard Therapy
por: Weichman, Brittani, et al.
Publicado: (2022)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

New antibiotics for Gram-negative pneumonia
por: Bassetti, Matteo, et al.
Publicado: (2022)

Cariprazine in Three Special Different Areas: A Real-World Experience
por: Gesi, Camilla, et al.
Publicado: (2021)

Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis
por: Liu, Taoming, et al.
Publicado: (2021)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes, Jose M, et al.
Publicado: (2021)

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia
por: Cheong, Wai Kwong, et al.
Publicado: (2022)

Real-world experience with histological confirmation of clinical response of squamous cell carcinoma to topical tirbanibulin
por: Moore, Angela, et al.
Publicado: (2023)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population()
por: Kuznicki, Michelle L., et al.
Publicado: (2020)

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)
por: Carvalhaes, Cecilia G., et al.
Publicado: (2022)

The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic
por: Reynolds, Daniel, et al.
Publicado: (2022)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard, JD, et al.
Publicado: (2019)

1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

Real-world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
por: Sahay, Sandeep, et al.
Publicado: (2020)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
por: Schmidt-Malan, Suzannah M., et al.
Publicado: (2019)

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus
por: Berti, Andrew D., et al.
Publicado: (2020)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022)

Health Emergency Risk Management in World Health Organization – South-East Asia Region during 2014–2023: synthesis of experiences
por: Salvador, Edwin Ceniza, et al.
Publicado: (2023)

The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies
por: Estrada, Sandy, et al.
Publicado: (2020)

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
por: Ben-Omran, Tawfeg, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mk2lg4090c7ju8vks635dsko21